Animalcare Group PLC (GB:ANCR)
LSE:ANCR
Top Page
Animalcare
(LSE:ANCR)
Select Model
Select Model
Rating:67Neutral
Price Target:
308.00 p
▲(29.41% Upside)
Action:ReiteratedDate:12/07/25
Animalcare's overall stock score reflects strong financial stability and positive corporate events, which are offset by valuation concerns due to a negative P/E ratio. Technical indicators suggest moderate potential for price appreciation. The company's strategic initiatives and director's confidence are significant positives.
Positive Factors
Strong balance sheet and low leverage
High equity ratio and minimal leverage provide durable financial flexibility, lowering refinancing and solvency risk. Improved ROE signals management is generating higher returns on capital, supporting sustained investment in growth and resilience through industry cycles.
Negative Factors
Recent revenue contraction
A recent decline in revenue signals challenges in top-line growth that can limit long-term margin expansion and reinvestment. Unless product uptake or geographic expansion accelerates, sustained revenue weakness could pressure profitability and strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet and low leverage
High equity ratio and minimal leverage provide durable financial flexibility, lowering refinancing and solvency risk. Improved ROE signals management is generating higher returns on capital, supporting sustained investment in growth and resilience through industry cycles.
Read all positive factors
Animalcare (ANCR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£161.57M
Dividend Yield2.18%
Average Volume (3M)66.93K
Price to Earnings (P/E)15.5
Beta (1Y)0.46
Revenue Growth8.74%
EPS Growth-166.50%
CountryUK
Employees226
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding69,045,944
10 Day Avg. Volume79,363
30 Day Avg. Volume66,930
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.32
Price to Sales (P/S)2.01
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)£93.84M
Animalcare Business Overview & Revenue Model
Company Description
Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals and identification products, and services for companion and production animals, and equine veterinary markets. It is also involved in th...
How the Company Makes Money
Animalcare generates revenue through multiple streams, primarily by selling its veterinary pharmaceuticals and products to veterinary practices, pet owners, and livestock producers. The company has established a strong presence in the European mar...
Animalcare Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 81.07M | 74.23M | 74.35M | 71.62M | 74.02M | 70.49M |
| Gross Profit | 37.52M | 34.06M | 43.35M | 40.66M | 39.42M | 36.56M |
| EBITDA | 14.03M | 13.43M | 11.82M | 11.04M | 10.15M | 10.30M |
| Net Income | 2.98M | 32.22M | 1.20M | 1.97M | -77.00K | 234.00K |
Balance Sheet | ||||||
| Total Assets | 163.87M | 158.81M | 106.79M | 118.24M | 110.00M | 124.44M |
| Cash, Cash Equivalents and Short-Term Investments | 9.92M | 11.71M | 4.64M | 6.04M | 5.63M | 5.26M |
| Total Debt | 21.02M | 24.01M | 5.88M | 11.44M | 10.96M | 18.88M |
| Total Liabilities | 50.62M | 45.50M | 28.90M | 39.26M | 31.20M | 42.84M |
| Stockholders Equity | 113.25M | 113.31M | 77.89M | 78.99M | 78.80M | 81.59M |
Cash Flow | ||||||
| Free Cash Flow | 11.12M | 11.72M | 7.73M | 6.48M | 10.81M | 8.68M |
| Operating Cash Flow | 11.41M | 11.93M | 10.28M | 9.43M | 14.02M | 11.12M |
| Investing Cash Flow | -63.51M | -34.85M | -2.86M | -3.12M | -2.96M | -2.91M |
| Financing Cash Flow | 29.22M | 32.53M | -8.95M | -5.70M | -10.96M | -8.86M |
Animalcare Technical Analysis
Negative
238.00
Price Trends
267.24
Negative
256.48
Negative
257.37
Negative
Market Momentum
-10.52
Positive
35.52
Neutral
36.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANCR, the sentiment is Negative. The current price of 238 is below the 20-day moving average (MA) of 251.55, below the 50-day MA of 267.24, and below the 200-day MA of 257.37, indicating a bearish trend. The MACD of -10.52 indicates Positive momentum. The RSI at 35.52 is Neutral, neither overbought nor oversold. The STOCH value of 36.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ANCR.
Animalcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £62.34M | -44.80 | 3.55% | ― | 1.44% | 359.79% | |
67 Neutral | £161.57M | 15.48 | 2.63% | 2.18% | 8.74% | -166.50% | |
65 Neutral | £77.36M | -8.91 | -0.12% | ― | ― | ― | |
63 Neutral | £91.88M | -1.10 | 206.44% | ― | 93.48% | 51.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GB:ANCR
Animalcare
234.00
27.26
13.19%
GB:EAH
Eco Animal Health
92.00
40.50
78.64%
GB:STX
Shield Therapeutics
8.60
5.85
212.73%
GB:VLG
Venture Life
63.50
24.50
62.82%
Animalcare Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Animalcare posts strong 2025 growth on Randlab deal and flagship brands
Positive
Jan 22, 2026
Animalcare reported a strong 2025 trading performance, with revenues up 20% to about £89.1m and underlying EBITDA rising roughly 50%, driven by the successful acquisition and integration of Randlab, double‑digit growth in flagship compa...
Business Operations and StrategyExecutive/Board Changes
Animalcare Grants New LTIP Share Options to Senior Executives
Positive
Dec 23, 2025
Animalcare Group has granted nil-cost options over 294,222 ordinary shares to its executive directors and other persons discharging managerial responsibilities under its Long Term Incentive Plan, marking the only such awards to executives in the 2...
Business Operations and Strategy
Animalcare Director Increases Stake with Share Purchase
Positive
Nov 19, 2025
Animalcare Group plc announced that Dr. Douglas Hutchens, a Non-Executive Director, purchased 7,500 ordinary shares at 249p each, increasing his total interest to 12,500 shares, representing 0.02% of the company’s voting rights. This transac...
Private Placements and FinancingRegulatory Filings and Compliance
Animalcare Group Announces New Share Issuance Following Option Exercise
Neutral
Nov 19, 2025
Animalcare Group plc announced the exercise of options under its Long Term Incentive Plan, resulting in the issuance of 56,873 new ordinary shares. These shares are expected to begin trading on AIM on 24 November 2025 and will have equal rights wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.